As a result, PHF8 may serve as a potential therapeutic target for KRAS- or BRAF-mutant CRCs, while PHF8 further contributes to the immune escape of CRC cells via c-Myc-mediated PD-L1 upregulation. The gene discussed is BRAF; the disease is colorectal carcinoma.